Chronic L‐DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice
Open Access
- 27 March 2015
- journal article
- research article
- Published by Wiley in Genes, Brain and Behavior
- Vol. 14 (3) , 260-270
Abstract
Dopamine (DA) replacement therapy continues to be the gold standard treatment for Parkinson's disease (PD), as it improves key motor symptoms including bradykinesia and gait disturbances. With time, treatment induces side effects in the majority of patients, known as L‐DOPA‐induced dyskinesia (LID), which are often studied in animals by the use of unilateral, toxin‐induced rodent models. In this study, we used the progressive, genetic PD model MitoPark to specifically evaluate bilateral changes in motor behavior following long‐term L‐DOPA treatment at three different stages of striatal DA depletion. Besides locomotor activity, we assessed changes in gait with two automated gait analysis systems and the development of dyskinetic behavior. Long‐term treatment with a moderate, clinically relevant dose of L‐DOPA (8 mg/kg) gradually produced age‐dependent hyperactivity in MitoPark mice. In voluntary and forced gait analyses, we show that MitoPark mice with severe DA depletion have distinct gait characteristics, which are normalized to control levels following long‐term L‐DOPA treatment. The cylinder test showed an age‐dependent and gradual development of bilateral LID. Significant increase in striatal FosB and prodynorphin expression was found to accompany the behavior changes. Taken together, we report that MitoPark mice model both behavioral and biochemical characteristics of long‐term L‐DOPA treatment in PD patients and provide a novel, consistent and progressive animal model of dyskinesia to aid in the discovery and evaluation of better treatment options to counteract LID.Keywords
Funding Information
- Swedish Brain Power
- Swedish Research Council (K2013-62X-20377-07-3)
This publication has 27 references indexed in Scilit:
- Modeling dyskinesia in animal models of Parkinson diseaseExperimental Neurology, 2014
- Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysisEJNMMI Research, 2013
- Enhanced striatal cholinergic neuronal activity mediatesl-DOPA–induced dyskinesia in parkinsonian miceProceedings of the National Academy of Sciences, 2010
- Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's diseaseJournal of Biomedical Science, 2010
- Lrrk2 and α-synuclein are co-regulated in rodent striatumMolecular and Cellular Neuroscience, 2008
- Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s diseaseNeurobiology of Disease, 2007
- Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neuronsProceedings of the National Academy of Sciences, 2007
- Striatal fosB Expression Is Causally Linked with l-DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's DiseaseNeurobiology of Disease, 1999
- L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNAEuropean Journal of Neuroscience, 1998
- An Open Multicenter Trial of Sinemet CR in Levodopa-Naive Parkinsonʼs Disease PatientsClinical Neuropharmacology, 1991